ADMA Biologics (NASDAQ:ADMA) Sees Large Volume Increase on Analyst Upgrade

ADMA Biologics, Inc. (NASDAQ:ADMA) saw an uptick in trading volume on Thursday after Raymond James raised their price target on the stock from $25.00 to $32.00. Raymond James currently has a strong-buy rating on the stock. 4,407,227 shares changed hands during trading, an increase of 19% from the previous session’s volume of 3,705,074 shares.The stock last traded at $19.10 and had previously closed at $23.61.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $35,000. GAMMA Investing LLC raised its holdings in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics during the fourth quarter worth $35,000. Tsfg LLC acquired a new stake in ADMA Biologics in the first quarter valued at $51,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of ADMA Biologics in the first quarter valued at $52,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Down 10.2 %

The firm has a market cap of $5.04 billion, a price-to-earnings ratio of 75.71 and a beta of 0.57. The firm has a 50 day moving average price of $20.17 and a 200-day moving average price of $18.69. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. During the same period last year, the business earned $0.08 earnings per share. The company’s revenue for the quarter was up 40.2% on a year-over-year basis. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.